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Abstract: Aggressive symptomatology presents across multiple psychiatric, 
developmental, neurological and behavioral disorders, complicating the diagnosis and 
treatment of the underlying pathology. Anti-Epileptic Drugs (AEDs) have become an 
appealing alternative in the treatment of aggression, mood lability and impulsivity in adult 
and pediatric populations, although few controlled trials have explored their efficacy in 
treating pediatric populations. This review of the literature synthesizes the available data 
on ten AEDs—valproate, carbamazepine, oxcarbazepine, phenytoin, lamotrigine, 
topiramate, levetiracetam, zonisamide, gabapentin and tiagabine—in an attempt to assess 
evidence for the efficacy of AEDs in the treatment of aggression in pediatric populations. 
Our review revealed modest evidence that some of the AEDs produced improvement in 
pediatric aggression, but controlled trials in pediatric bipolar disorder have not been 
promising. Valproate is the best supported AED for aggression and should be considered 
as a first line of treatment. When monotherapy is insufficient, combining an AED with 
either lithium or an atypical anti-psychotic can result in better efficacy. Additionally, our 
review indicates that medications with predominately GABA-ergic mechanisms of action 
are not effective in treating aggression, and medications which decrease glutaminergic 
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transmission tended to have more cognitive adverse effects. Agents with multiple 
mechanisms of action may be more effective. 
Keywords: aggression; anti-epileptic drugs (AEDs); pediatric bipolar disorder 
 
1. Introduction 
Aggression is not in itself a syndrome; it is a non-pathognomonic symptom that represents a 
common phenotype to multiple psychiatric illnesses (Table 1). Characteristics of aggression implicate 
different etiologies. Consequently, there is a difference in treating the aggression of an adolescent male 
experiencing his first psychotic break compared with that of a latency age female with a history of 
physical and sexual abuse, showing clinically significant anger and irritability towards others. The 
underlying pathology can be inferred from the severity and duration of the aggressive episode (Table 1). 
The appropriate diagnosis and treatment of aggression in children and adolescents presents a unique 
dilemma in clinical care [1].  
Defining diagnostic categories for the varied types of aggression remains one of the more 
controversial issues within the field of pediatric mental health. By the Diagnostic and Statistical Manual 
of Mental Disorders’ (DSM-IV) [2] criteria, most children presenting with severe mood dysregulation 
meet for either the Attention Deficit Hyperactivity Disorder (ADHD) spectrum disorders implicated by 
short aggressive outbursts, or mood disorders implicated by more prolonged episodes. The current debate 
dictating future changes to the DSM centers on the argument that the existing diagnostic structure 
precludes adequate diagnosing of children presenting with mood dysregulation that is not accounted for 
by Bipolar or ADHD spectrum diagnoses [3]. As a result, a new diagnosis of Temper Dysregulation 
Disorder with Dysphoria (TDD) has been proposed for the upcoming DSM-V to create a more accurate 
diagnostic construct for aggression [3]. The defining symptoms of this disorder include at least 
12 months (with remittance no longer than three months) of severe temper outbursts that occur an 
average of three times a week in response to common stressors which manifest verbally or behaviorally 
and are disproportionate to the event as well as developmentally inappropriate [4]. The onset of the 
disorder should occur before 10 years of age, and is defined by persistent negative emotionality that does 
not occur exclusively in the context of a mental, psychotic or mood disorder [4]. However, the diagnosis 
can coexist with behavioral disorders such as Oppositional Defiant Disorder (ODD), ADHD, Conduct 
Disorder, and Substance Use disorders [4].  
The different characteristics of aggression implicate different etiologies. The most effective and 
appropriate management of aggression can occur when there is an understanding of the etiology of the 
aggressive symptoms [1]. Focusing treatment to address a specific target of core symptoms can better 
guide treatment decisions [1]. For example, a patient with an agitated depression may respond well to 
an SSRI [1]. The adolescent with new onset psychosis, however, may do better with an atypical 
anti-psychotic [1]. The treatment plan should be created after close consideration of the risks and 
benefits of intervention possibilities for each particular patient. Parents need to understand the risk for 
self-harm, harm to others, and possible destruction of property that can occur with aggressive episodes. 
Likewise, they should understand the significant side-effects of medications that are being considered. Pharmaceuticals 2010, 3 
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In formulating a treatment plan, it is important to consider the use of all treatment modalities. There 
are effective non-psychopharmacological interventions to treat aggression, as well as other non-
antiepileptic drug (AED) medications which have been proven efficacious. Due to the scope of this 
article, the discussion will be limited to the role of AEDs in the treatment of aggressive symptoms. 
Table 1. Differentiation of aggression etiologies by clinical characteristics [1]. 
Outbursts Arising Out of Affective States 
Outbursts Arising from Cognitive 
States 
Brief Impulsive Outbursts / Mild to 
Moderate Intensity:  
Attention Deficit Hyperactivity Disorder 
Impulse Control Disorders 
Intermediate Duration / Moderate to severe 
Intensity: 
Major Depressive Disorder 
Acute Stress Disorder 
PTSD – Exposure to Abuse/Violence 
Panic and other Anxiety Disorders 
Adjustment Disorder with Disturbance of 
Conduct 
Borderline Personality Disorder 
Prolonged Outbursts / Severe Intensity: 
Bipolar Spectrum Disorder- Mania and 
Mixed Mania 
Temper Dysregulation Disorder with 
Dysphoria 
Outbursts Arising due Cognitive 
Disturbances/ confusion: 
 Mental Retardation 
 Pervasive Developmental Disorders 
 Psychotic Spectrum Disorder 
 Delirium 
Outburst During Acute Intoxication or 
Withdrawal: 
Substance Related Disorders 
Outbursts Premeditated to Achieve 
Desired Effect or Goal: 
Conduct Disorder 
Antisocial Personality Disorder 
Narcissistic Personality Disorder 
2. Why AEDs? 
Although the atypical antipsychotics are very effective and used fairly commonly in the treatment 
of pediatric aggression, there is concern about their use in the pediatric population due to the incidence 
of metabolic abnormalities, diabetes mellitus, weight gain, insulin resistance, hyperlipidemia, 
neuroleptic malignant syndrome, dystonias and other extra-pyramidal reactions, including possible 
tardive dyskinesia [1]. Newer AEDs have improved side effect profiles and have shown some efficacy 
in adults for treating aggressive symptoms. AEDs may represent a more tolerable long-term treatment 
for aggression in children and adolescents [1]. In addition, despite the efficacy of atypical anti-
psychotics, there are patients who do not respond to monotherapy. A possible augmentation strategy 
can include combined treatment with an AED. 
3. Methods and Limitations 
There is a limited knowledge base of well-designed, randomized, double-blind, placebo-controlled 
clinical trials in children and adolescents addressing the use of AEDs for aggression and/or mood 
lability. One of the greatest difficulties in assessing the literature is that most studies of aggression do 
not differentiate the etiology of aggression by diagnosis. Current diagnostic construct and outcome Pharmaceuticals 2010, 3 
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measures of “prolonged severe aggressive episodes” vary in clinical trials. The two most common are 
Bipolar Spectrum Disorders and Oppositional Defiant Disorder/Conduct Disorder with ADHD; with 
the former often measured using the Young Mania Rating Scale (YMRS) as an outcome measure and 
the later often measured using the modified overt aggression scale (MOAS).  
For this review, the Medline database was searched for articles on aggression or bipolar disorder 
(especially pediatric) for each of the available AEDs. Search terms included “aggression”, “bipolar 
disorder”, “pediatric” and “anti-epileptic drugs”. Uncontrolled studies and chart reviews were excluded 
where controlled clinical trials were available. Existing data were first reviewed and then synthesized 
clinically to determine current best evidence-based treatment guidelines.  
4. Results and Dissussion 
AED’s have diverse mechanisms of action. The principal mechanism can be conceptualized as 
belonging to one of three main groups based on their predominant neurochemical effect: blockage of 
voltage-gated ion channels (Na and Ca), enhancement of GABA-ergic inhibition, and reduction of 
glutamatergic excitation [5]. AED’s may exert their action through one or more of these three 
mechanistic classes. For example, AED’s that work by primarily enhancing GABA-mediated 
transmission include tiagabine and gabapentin while those that block voltage-gated ion channels 
include carbamazepine, oxcarbazepine, phenytoin and lamotrigine.  
Antiepileptic drugs with higher risk of paradoxically aggravating seizures are more likely to 
participate in only one or two known mechanisms of action: either the blockade of voltage-gated 
sodium channels or facilitation of increased GABA-mediated transmission. Antiepileptic drugs that are 
less likely to aggravate seizures have multiple mechanisms of action identified [6]. It seems from our 
review, that in a similar manner, AEDs that have multiple mechanisms of action are more effective in 
the treatment of aggression (as with seizures) than the AEDs that have only one or two mechanisms of 
action, and that the latter are more likely to cause paradoxical worsening of aggression.  
4.1. Valproate 
Of all the AEDs, the most evidence-based data currently exists for the use of valproate in the 
treatment of aggression. Evidence-based data has supported the efficacy of vaplroate in reducing 
symptoms of bipolar disorder in adults [7-10]. In adults, valproate has shown comparable efficacy to 
lithium [11] and superior efficacy to carbamazepine in the treatment of pure mania [12]. It is better 
than lithium for mania mixed with depression [12], and its efficacy is not well-established for acute 
bipolar depression. For prophylaxis, valproate appears to be better at preventing manic versus 
depressive breakthrough, but is likely inferior to lithium at preventing suicide [13]. There is an 
approximately 80% relapse rate with lithium or valproate monotherapy [14]. 
The available data for the use of valproate in youth with bipolar disorder is more conflicting. A 
retrospective chart review of 15 children and adolescents with bipolar disorder aged 4-18 indicated a 
53% response rate after treatment with valproate for greater than one year [15]. However, a recent 
double-blind trial of extended-release valproate in children and adolescents aged 10-17 with bipolar 
disorder found that the drug did not differ from placebo after a 4-week treatment period [16]. Pharmaceuticals 2010, 3 
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A 12-week open-label trial of valproate in bipolar offspring at high risk for developing the disorder 
showed a 71% response rate to treatment based on improved scores on the Overt Aggression Scale [17]. 
In contrast to these results, a double-blind trial comparing valproate to placebo in youth at high risk for 
developing bipolar disorder found no difference between the treatment and control groups [18]. 
Further controlled trials are clearly necessary to evaluate the efficacy of valproate in this population. 
Valproate has also been widely used in the treatment of aggression. A small study by Donovan and 
colleagues [19] followed 10 disruptive adolescents who met criteria for explosive mood disorder and 
were given open-label valproate for five consecutive weeks. All showed significant improvement and 
were either in remission or close to remission by the end of the study. In a later double-blind crossover 
trial of youth with explosive temper and mood lability, an 86% response rate to valproate was found 
compared to a 25% response rate for placebo [20]. While this study excluded patients with the 
diagnosis of bipolar disorder, many of the target symptoms in the study overlapped with those used in 
pediatric bipolar studies.  
Additional double-blind trials have supported the efficacy of valproate in treating impulse control 
amongst youth with conduct disorder [21]. Steiner et al. [21] compared high dose valproate to low 
dose valproate and monitored global severity in youth with conduct disorder. The patients receiving 
high dose valproate had greater improvements in their global severity rating score without a significant 
difference in tolerability to the valproate. Preliminary data also suggests that when valproate is used as 
an adjunctive treatment, it reduces aggression in children with co-morbid ADHD and disruptive 
behavior disorders who were refractory to stimulant monotherapy [22].  
While double blind trials have supported its efficacy in treating irritability in children and 
adolescents with Autism Spectrum disorders [23], a double-blind trial evaluating valproate for 
aggression in youth with Pervasive Developmental disorders did not yield significant differences from 
placebo [24]. These results may be attributed to low power [24].  
McVearry, et al. [25] recently described an increased risk of impaired cognitive function at 3 years 
of age in children who had in-utero exposure to valproate, as compared with other commonly used 
AEDs (lamotrigine and carbamazepine). Bromley, et al. [26] also found delayed early development in 
children with in-utero exposure to valproate. This finding supports a recommendation that valproate 
should not be used as a first-choice drug in women of childbearing potential. 
4.2. Carbamazepine 
In adults, carbamazepine has well established efficacy in treating aggressive symptoms in a variety of 
psychiatric, cognitive and neurological disorders. In the few studies using pediatric populations, results 
have been mixed, with larger scale trials failing to find statistically significant improvements in aggression. 
In a pilot study of carbamazepine in hospitalized aggressive and explosive children with a diagnosis 
of conduct disorder, significant declines in aggressiveness and explosiveness were demonstrated [27]. 
However, in a larger double blind placebo controlled study using a similar population of aggressive 
children with conduct disorder, carbamazepine showed no superiority over placebo [28]. In 
hospitalized pre-adolescents with bipolar disorder, a recent chart review found both lithium and 
diavalproex to be more efficacious than carbamazepine by the second week of hospitalization [29].  Pharmaceuticals 2010, 3 
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Recently, controlled trials have explored the use of carbazepine in treating impulsive behavior in 
children and adults, with conflicting results in the varied populations. A double blind, placebo controlled 
trial found it to be an effective treatment for impulsive aggression in adult males, however, its treatment 
effect was slightly delayed when compared to valproate and phenytoin [30]. In a prospective randomized 
controlled study comparing clonidine to carbamazepine in the treatment of ADHD in children, clonidine 
was found to be more effective in treating impulsivity and hyperactivity [31]. Currently, carbamazepine 
has FDA Black Box warnings for aplastic anemia and agranulocytosis (both have an incidence of 1  
in 100,000). 
4.3. Oxcarbazepine 
There is limited data regarding the psychiatric use of oxcarbazepine in children and adolescents. 
Two studies in the treatment of adult bipolar disorder have been promising. In a double-blind, 
placebo-controlled trial of oxcarbazepine in patients with impulsive aggression and no known 
psychiatric comorbidities, analyses showed consistent evidence of benefit from oxcarbazepine 
compared with placebo [32].  
In a double-blind randomized controlled trial of oxcarbazepine vs. placebo in children 7 to 18 years 
of age with Bipolar I disorder, either manic or mixed, oxcarbazepine did not significantly improve 
YMRS scores at endpoint compared with placebo [29]. Dizziness, nausea, somnolence, diplopia, 
fatigue, and rash were each reported in at least 5% of the patients in the oxcarbazepine group with an 
incidence at least twice that found in the placebo group [33]. The majority of adverse events was mild to 
moderate and occurred during the titration period [33]. Eleven patients (19%) in the oxcarbazepine group 
discontinued the study because of adverse events, compared with two (4%) in the placebo group [33]. 
Fairly recently, the FDA released a warning of possible serious adverse dermatological reactions, 
including Stevens Johnson syndrome and toxic epidermal necrolysis, as well as multi-organ 
hypersensitivity reactions in children and adults treated with oxcarbazepine. There is a need for better 
efficacy and tolerability data before oxcarbazepine can be considered a first line anti-aggressive agent 
for children and adolescents. The advantages to using oxcarbazepine are that it does not require 
elaborate lab testing and has less associated weight gain than valproate [1]. 
4.4. Phenytoin 
Prior to the 1990s, studies of the effects of phenytoin on aggression produced conflicting results 
because of failure to use objective measures of aggression across studies, lack of rigorous inclusion 
and exclusion criteria for selecting subjects, and non-differentiation between various types of 
aggression [34]. However, more recent double-blind, placebo-controlled crossover trials have indicated 
that phenytoin significantly reduces episodes of impulsive aggression in adults [34,35]. Controlled 
trials of phenytoin for adult patients with bipolar disorder suggest that the drug is effective in treating 
mania [36] and has prophylactic effects when used as an add-on medication for bipolar patients who 
had been stable for at least 1 month [37,38]. Unfortunately, no studies to date have looked at the 
effects of phenytoin on bipolar disorder or aggression in children. 
 Pharmaceuticals 2010, 3 
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4.5. Lamotrigine 
Lamotrigine was approved in 2003 for maintenance therapy of adults with Bipolar I Disorder. It has 
a recommended slow titration schedule due to the risk of Stevens Johnson Syndrome, and for this 
reason is not recommended for the treatment of acute aggression. Some studies indicate a possible 
paradoxical increase in aggression with some patients. A recent open-label trial of the drug followed 46 
pediatric bipolar patients for a duration of 14 weeks [39]. The response rates for manic and depressive 
symptoms were 72% and 82%, respectively, and the remission rate was 56%. An older open-label 
study also yielded positive results, suggesting that lamotrigine is effective either as an adjunctive 
treatment or as monotherapy in treating pediatric depression, mania, and aggression [40]. A double-blind 
placebo-controlled trial is currently underway to assess the efficacy of lamotrigine as an add-on 
treatment for children and adolescents with bipolar disorder. 
In adult double-blind studies, it has been shown to be particularly useful in prevention of relapse 
into depression. In placebo-controlled studies of bipolar depression by Calabrese et al., secondary 
outcomes for lamotrigine monotherapy at 200 mg were significant when compared to monotherapy at 
50 mg and placebo [41]. In a comparison of lamotrigine to placebo in Bipolar I and II depressed 
patients, no overall difference was found. However, a separate analysis of the Bipolar I subgroup 
found better response on lamotrigine than placebo [41]. While lamotrigine may be effective for 
prophylaxis of bipolar depression, it would not be recommended for acute aggression due to the 
necessity for a slow titration.  
4.6. Topiramate 
Topiramate has been shown to be an effective treatment for aggression in adult populations with 
borderline personality disorders in double blind placebo controlled trials, with improvements 
maintained at 18 month follow up [42-44]. Based on 14 open label studies, the drug had an overall 
58% response rate in 279 adult patients with Bipolar disorder [1]. In double-blind placebo-controlled 
studies, Yatham et al. [45] and Calabrese et al. [46] reported that topiramate had no difference in 
primary outcomes for acute mania, but did show better efficacy on secondary outcomes.  
Pediatric studies using small samples of children with Autism Spectrum disorders have not found 
topiramate to be an effective agent in reducing self-injurious behaviors. In one such study using a 
sample of 5 severely impaired boys with Autism Spectrum disorders aged 9-13, topiramate was not 
found to be substantially effective over a treatment period ranging from 10-33 weeks [47]. In a sample 
of 10 children and adolescents aged 8-19 with Autism Spectrum disorder who were on antipsychotic 
medication, topiramate (added on to counteract neuroleptic-induced weight gain) caused “behavioral 
adverse effects” in three patients, requiring rapid withdrawal of this medication [48]. The authors 
concluded that topiramate should be used with caution in Autism Spectrum disorders [48]. 
Additionally, topiramate, among the newer AEDs, has the greatest risk for cognitive impairment [49]. 
In pediatric populations, chart reviews have suggested the possible efficacy of topiramate as an 
adjunctive treatment for bipolar disorder, however this has not been confirmed in controlled trials. In a 
retrospective chart review looking at 26 patients with a diagnosis of bipolar disorder between the ages 
of 10-18, topiramate was found to be a well tolerated and effective adjunctive treatment [50]. Pharmaceuticals 2010, 3 
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However, a pilot double blind placebo controlled trial examining the efficacy of topiramate for mania 
in 56 children and adolescents with bipolar disorder was discontinued when adult mania trials failed to 
show efficacy [51]. In another more recent retrospective chart review of 25 hospitalized children and 
adolescents with bipolar disorders receiving topiramate as an adjunctive treatment, topiramate was 
found to be effective for acute, manic, mixed, or depressive episodes [52].  
Perhaps the greatest demonstrated advantage to the use of topiramate compared with other AED’s is 
the associated weight loss. In two open label trials looking at topiramate as monotherapy [53,54] or as 
an adjunctive treatment [53], both found significant reductions in weight or reduced weight gain.  
4.7. Levetiracetam 
Levetiracetam has been explored as a treatment for aggression and impulsivity in a number of 
different adult populations, with mixed effectiveness outcomes. In a small open label on-off-on study 
design of adjunctive levetiracetam therapy with 10 acutely manic adults with Bipolar I disorder, 
improvements were found during the “on” phase [55]. However, a larger 10 week double blind placebo 
controlled trial of 40 outpatients with clinically significant impulsive aggression, did not find 
levetiracetam to be effective in reducing patient aggression [56].  
In the pediatric population, levetiracetam has been studied as a potential treatment for the 
impulsivity, aggression and mood lability associated with autism. Earlier open label trials using 
smaller samples indicated potential efficacy of levetiracetam as a treatment for aggression in autistic 
populations, with these findings not being confirmed in larger controlled trials. An open label study of 
the effectiveness of levetiracetam in a sample of 10 autistic boys aged 4-10 found significant 
reductions in inattention, hyperkinesis and impulsivity [57]. In a larger 10 week double blind placebo 
controlled study of 25 autistic patients aged 5-17, findings of the effectiveness of levetiracetam in 
treating the behavioral disturbances associated with autism was not confirmed [58]. 
There have been reports of behavioral changes, mostly negative (including aggression), in patients 
taking levetiracetam [59]. Due to the lack of good evidence base in supporting the efficacy of 
levetiracetam for aggression, and reports of worsening aggression, we do not support the use of this 
medication as a first-line treatment of aggression. 
4.8. Zonisamide 
There is very little data available regarding the use of zonisamide for aggression. Thus far, it has 
primarily been utilized in the treatment of bipolar depression. In an open-label study of bipolar and 
schizoaffective manic adults, 71% showed significant global improvement on zonisamide [60]. 
Another preliminary study of zonisamide in 10 patients with bipolar depression found significant 
clinical global improvement scores and reduction in depressive symptoms [61]. However, there was no 
significant effect of the drug on improving mania scores in these patients. The most recent study of 
zonisamide for bipolar depression found the drug to have modest effectiveness and a low switch rate to 
mania, but the authors did not recommend its use as a first line treatment due to a high side-effect 
profile [62]. To date, zonisamide has not been studied for the psychiatric treatment of children. 
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4.9. Gabapentin 
Gabapentin is generally not useful for aggression. An exception is that it may prove helpful in select 
cases where anxiety or pain is leading to aggression [63].  
In a review on the use of gabapentin in mood disorders in adult populations, 40 open-label studies 
and four controlled trials were identified [64]. Based on the open-label studies and two of the 
controlled trials, the authors concluded that gabapentin may have a possible benefit as an adjunctive 
agent in treating refractory and co-morbid bipolar disordered patients [64]. However, we consider this 
to be an overly optimistic conclusion, given that the two trials that were positive had small sample 
sizes and although the findings were presented at conferences/meetings, we were unable to find these 
published in the peer-reviewed literature. The two controlled trails that did not show evidence of 
gabapentin’s superiority to placebo have been published in peer-reviewed journals [63,65].  
In the pediatric literature, gabapentin has been noted to worsen and even induce aggression in 
certain populations [66]. It has also been reported to cause aggressive and oppositional behavior in 
pediatric patients with seizures [67,68]. 
4.10. Tiagabine 
Tiagabine is a GABA-reuptake inhibitor which requires slow titration due to the significant adverse 
effects noted in open label studies [1]. Due to the purported relationship between GABA and 
aggressive behavior in humans, a recent study looked at the effect of acute tiagabine administration on 
the aggressive response rate of 10 adult male parolees, with findings indicating that tiagabine 
decreased aggressive responding in some domains of laboratory response tasks [69]. 
There have been a number of open label trials testing the effectiveness of tiagabine in treating adult 
patients with bipolar disorder. In an open label trial of eight acutely manic adult patients with a 
diagnosis of Bipolar I disorder receiving either tiagabine monotherapy (n = 2) or adjunctive tiagabine 
(n = 6), there were no reductions in mania over the 2 week observation period, and severe side effects 
such as nausea, vomiting and tonic-clonic seizure occurred in two patients [70].  
Adult open label trials of tiagabine as an adjunctive treatment for refractory bipolar disorder have 
yielded mixed results. In an open label trial of tiagabine as an add-on treatment for 17 treatment 
refractory adult bipolar patients, there was a 23% response rate with 77% showing no change or 
worsening symptoms [71]. Another open label trial of tiagabine as an adjunctive treatment for 
22 refractory bipolar patients found a 36% response rate [72]. However, 64% of patients in this study 
also had to discontinue the medication secondary to adverse effects [72]. 
Recently, after more than 30 post-marketing reports of new onset seizures and status epilepticus in 
patients with no history of epilepsy, the FDA has issued a warning of the incidence of de-novo seizures 
in patients treated off-label with tiagabine. No pediatric trials were identified from the literature for 
this review. 
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4.11. Head to Head Comparisons 
There have been few studies comparing the efficacy of AEDs with each other in the treatment of 
pediatric aggression. MacMillan and colleagues [73] compared divalproex, oxcarbazepine, and 
gabapentin in youth with aggression and found that although the percentage of responders at 6 months 
did not differ significantly between groups, there were significant differences in discontinuation rates. 
Gabapentin and oxcarbazepine had higher rates of discontinuation due to worsening of aggression, 
13.3% and 14.3% respectively, when compared to divalproex (0.0%). In addition, more patients in the 
gabapentin group (40%) were worse overall at the end of the observation than in either the 
divalproex (13.8%), or oxcarbazepine (19%) groups. In a study by Kowatch et al. [73,74] comparing 
monotherapy with valproate, lithium, or carbamazepine in children and adolescents with bipolar 
disorder, response rates were 53%, 38%, and 38% respectively. Results from these studies implicate 
valproate as the most efficacious AED in the treatment of pediatric aggression. 
4.12. Combined Pharmacotherapy 
The review of this literature seems to suggest greater efficacy with combination treatment. In an open-
label study of combined treatment with divalproex and lithium in pediatric patients with bipolar disorder, 
Findling et al. [18] found that 47% met the stronger a priori criteria for remission. Kowatch et al. [75] 
conducted a 16 week extension phase of monotherapy treatment with valproate, carbamazepine, or 
lithium. Among those patients that did not respond to monotherapy, 80% responded to a combination 
of two mood stabilizers. 
In a study by Findling et al. [76], 139 youth aged 5-17 with Bipolar I or II Disorder were initially 
treated with lithium plus valproate for approximately 11 weeks. Patients meeting remission criteria for 
four consecutive weeks were then randomized in a double-blind fashion to treatment with either lithium 
or valproate for up to 76 weeks. The lithium and valproate treatment groups did not differ in survival 
time until emerging symptoms of relapse or in survival time until discontinuation for any reason. 
In an open-label prospective trial of risperidone in combination with lithium or divalproex sodium 
in pediatric mania, 37 subjects aged 5 to 18 with DSM IV current mixed or manic episode were 
sequentially assigned to either valproate plus risperidone or lithium plus risperidone in a 6-month, 
prospective open-label trial [77]. Effect sizes based on change of YMRS scores from baseline were 
4.36 for valproate plus risperidone and 2.82 for lithium plus risperidone. Response rates were 80% for 
valproate plus risperidone and 82.4% for lithium plus risperidone [77]. Both combination treatments 
were well tolerated [77]. There were no significant group differences in safety or tolerability and no 
serious adverse events during the 6-month trial [77].  
In a retrospective chart review, DelBello et al. [78] found that when divalproex was combined with 
quetiapine in juvenile patients with Bipolar Disorder, significantly more reached remission criteria as 
compared to divalproex alone. These patients, however, also had increased weight gain. 
Gonzalez-Heydrich et al. conducted a retrospective chart review of hepatic enzyme levels during 
treatment with olanzapine, divalproex, or a combination of olanzapine and divalproex treatment. Patients 
on combined olanzapine and divalproex therapy had an increased risk of elevated hepatic enzymes 
compared to those on divalproex or olanzapine as sole mood stabilizers, including two of 12 patients Pharmaceuticals 2010, 3 
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with elevations greater than three times the normal range [79]. Combination treatment was 
discontinued due to pancreatitis in one child and steatohepatitis in another. 
Thus it seems that combination treatment of an AED with another AED, or lithium, or an atypical 
antipsychotic, is more efficacious than treatment with one AED alone. However, the incidence of side 
effects is also higher. 
5. Conclusion: Summary of the Efficacy of AEDs in Pediatric Aggression 
From the available data regarding the efficacy of treating pediatric aggression with AEDs, two trends 
were observed. First, medications with predominately GABA-ergic mechanisms of action have not been 
found to be effective in treating aggression, as demonstrated by the data from trials of gabapentin and 
tiagabine, with results demonstrating little efficacy or exacerbation of symptomatolgy [1]. It is not 
known why a predominate effect of increasing GABA activity can frequently lead to a paradoxical 
increase in aggression. That similar effects have been seen with such GABA agonists as ethanol and 
benzodiazepines, implies that some degree of facilitation of impulsive behavior is occurring. There is 
some evidence that medications which work by stabilizing the sodium and calcium channels may be 
helpful, indicated by valproate, the AED with the most evidence based data [1]. Secondly, agents with 
multiple mechanisms of action may be more effective. This second trend may explain an apparent 
contradiction that enhanced GABA activity, when accompanied by additional antiepileptic 
mechanisms, does not lead to the same high rate of paradoxical worsening of aggression. For example, 
valproic acid’s potential enhancement of GABA mechanisms at higher doses, together with its actions on 
sodium and calcium channels, may provide a possible explanation for the more robust improvement seen 
with valproate at higher doses compared to that seen for carbamazepine [1]. This leads to the potentially 
testable hypothesis that adding a pure GABA enhancing agent to an agent such as carbamazepine may 
augment its effect. Finally, medications like topiramate which decrease glutaminergic transmission 
tended to have more cognitive adverse effects [1]. 
While there is a limited knowledge base of well-designed, randomized, double-blind, placebo-
controlled clinical trials in children and adolescents addressing the use of AEDs for aggression and/or 
mood lability, currently, the strongest evidence exists for valproate. It has the added benefit of being 
loaded quickly at an approximate 20-30 mg/kg daily dose with a target steady state blood level 
between 80 and 125 mcg/mL [1]. Common adverse reactions include weight gain, liver function and 
platelet abnormalities [1]. Rare cases of hepatic necrosis and pancreatitis must be watched for; and 
drug blood levels, serum amylase, plasma ammonia, liver function tests, and platelets need to be 
monitored [1]. Patients doing poorly on valproate should first have their blood level checked and 
dosage optimized as patients receiving high dose valproate had greater improvements in their global 
severity rating score [21]. Due to the evidence for early cognitive delays in children exposed to 
valproate in-utero [25,26], we do not recommend valproate as a first-line agent for the treatment of 
aggression in females of child-bearing age. 
When monotherapy is not sufficient, combining an AED with either lithium or an atypical anti-
psychotic can result in better efficacy, but may also lead to more weight gain, metabolic side-effects, 
and liver toxicity [1]. Also, a more careful differential diagnosis of aggression and identification of Pharmaceuticals 2010, 3 
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patients that might respond to ADHD or antidepressant medication is warranted. When using 
combined treatments, more careful monitoring and discussions of risks and benefits is warranted [1] 
Our review of the literature reveals that most of the AEDs show significant improvement in 
pediatric aggression, however, not a clear improvement in pediatric bipolar disorder. The definition of 
pediatric bipolar disorder is currently controversial, and most patients currently diagnosed with 
pediatric bipolar disorder do not actually meet strict DSM-IV definitional criteria. The authors of the 
next edition of the DSM, the DSM-V, propose to deal with this nosological challenge by introducing a 
new diagnosis, “Temper Dysregulation Disorder with Dysphoria” [80] to include most cases currently 
being diagnosed as pediatric bipolar disorder. We feel that this change will be a step in the right 
direction, given what we have found in our literature review with these AED’s: that pediatric 
aggression is a phenotype that is distinct from pediatric bipolar disorder at least as far as treatment is 
concerned. However, it remains to be seen if this change in DSM terminology will actually occur. 
It is worth mentioning that although all AEDs now carry a controversial FDA mandated warning 
regarding a potential increase in suicidality [1], there has been recent evidence that AEDs do not 
increase the risk of suicide attempts in patients with bipolar disorder compared to untreated patients, 
and that the use of AEDs actually decreases the rates of suicide attempts relative to untreated patients 
and relative to the patients’ pretreatment levels [81]. 
Finally, the authors would also like to make a brief mention of Lithium, which, although beyond the 
scope of this review on account of it not being an AED, has been extensively used for impulsive 
aggression and especially bipolar disorder and aggression stemming from mania. It has been shown to 
be better than placebo in three of five placebo controlled studies [82-83]. 
Table 2. Summary of available evidence on AEDs for pediatric aggression (studies in 
adults are not included). 
AED  PROS and Positive Results  CONS and Negative Results 
VALPROATE 
 
Most evidence 
based data of all the 
AEDs 
 
•  Double blind trials support its efficacy in treating 
impulse control amongst youth with conduct 
disorder [21]. 
•  86% response rate (compared to 25% for placebo) 
in a double blind crossover trial of youth with 
explosive temper and mood lability [20]. 
•  71% response rate in bipolar offspring at high risk 
of developing the disorder in an open label trial 
[17]. 
•  53% response rate in children with bipolar disorder 
after treatment with Valproate for greater than 1 
year based on a retrospective chart review [15]. 
•  Some double blind placebo controlled trials have 
supported its efficacy in treating irritability (not 
aggression) in children and adolescents with 
Autism Spectrum Disorders [23]. 
•  Preliminary data suggests that as an adjunctive 
treatment, it reduces aggression in children with co-
morbid ADHD and disruptive behavior disorders 
who were refractory to stimulant monotherapy [22]. 
 
•  No difference to placebo in the treatment of 
Bipolar Disorder [16] and also those at high risk 
for developing Bipolar Disorder [18] in double 
blind placebo controlled trials. 
 
•  No significant difference from placebo in a double 
blind placebo controlled trial evaluating efficacy in 
treating aggression in Pervasive Developmental 
Disorders [24] (result may be due to low power). 
 
•  Increased risk of impaired cognitive function in 
children with in utero exposure to valproate 
compared to other commonly used AEDs [25]. 
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Table 2. Cont. 
CARBAMAZEPINE 
 
In adults, 
carbamazepine has 
well established 
efficacy in treating 
aggression, but in 
the few studies using 
pediatric 
populations, results 
have been mixed. 
 
•  Significant declines in aggressiveness and 
explosiveness in aggressive and explosive children 
with conduct disorder were demonstrated in an 
open label trial [27]. 
•  Superiority of carbamazepine over placebo in 
aggressive and explosive children with conduct 
disorder not confirmed by double blind placebo 
controlled trials [28]. 
 
•  Less effective than clonidine in treating 
impulsivity and hyperactivity in children with 
ADHD based on results from a randomized 
controlled trial [31]. 
•  FDA Black Box warnings for aplastic anemia 
and angranulocytosis (both have an incidence of 
1 in 100,000). 
OXCARBAZEPINE 
 
Limited data 
regarding its use in 
pediatric population. 
Two studies for 
treating adult bipolar 
disorder were 
promising. 
•  It does not require elaborate lab testing. 
•  Has less associated weight gain than valproate. 
•  No superiority to placebo for children with 
Bipolar I, manic or mixed, found in a double-
blind randomized controlled trial. 
•  FDA Warning of possible serious adverse 
dermatological reactions including Stevens 
Johnson syndrome and toxic epidermal 
necrolysis and multi-organ hypersensitivity 
reactions 
 
PHENYTOIN 
 
 
Although controlled trials have shown efficacy in treating aggression and mania in adults, no studies have 
looked at the effects of phenytoin on bipolar disorder or aggression in children 
 
LAMOTRIGINE  •  In a recent open label study of pediatric bipolar 
patients a response rate of 72% was found for 
manic symptoms and 82% for depressive 
symptoms. The remission rate was 56% [39]. 
 
•  Not recommended for acute aggression due 
to the slow titration requirement. 
TOPIRAMATE  •  There is associated weight loss – 2 open label trials 
showed significant reductions in weight or reduced 
weight gain [53,54]. 
•  Chart reviews [50,52] have suggested the possible 
efficacy of topirimate as an adjunctive treatment for 
pediatric bipolar disorder, however this has not 
been confirmed in controlled trials. 
•  A double blind placebo controlled trial of 
topirimate for mania in children with bipolar 
disorder was discontinued when adult trials 
failed to find efficacy [51]. 
•  Has not been found to be an effective 
treatment for reducing self injurious 
behaviors in children with Autism Spectrum 
Disorders [47,48]. 
•  Among the newer AEDs, has the greatest risk 
for cognitive impairment [49]. 
 
LEVETIRACETAM  •  Earlier, small open label trials suggested efficacy of 
levetiracetam as a treatment for aggression in 
pediatric populations [57], but this was not 
confirmed in controlled trials. 
•  Double blind placebo controlled trials have 
not found levetiracetam to be effective in 
treating the behavioral disturbances 
associated with autism in the pediatric 
population [58]. 
•  There have been reports of negative 
behavioral changes, including aggression, in 
patients taking levetiracetam [59]. 
ZONISAMIDE  Not studied for the psychiatric treatment of children 
GABAPENTIN 
 
 
•  May prove helpful in select cases, where anxiety or 
pain is leading to aggression [63]. 
•  Noted to worsen and even induce aggression in 
certain pediatric populations [66]. 
•  It has been reported to cause aggressive and 
oppositional behavior in pediatric patients with 
seizures [67,68]. 
TIAGABINE 
 
No pediatric trials 
  •  FDA has issued a warning of the incidence of de-
novo seizures in patients treated with off label 
tiagabine. 
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